Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014859 · ClinicalTrials.gov registry record
Epidemiology of Surfactant Protein-B Deficiency
A clinical trial, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- 5,176
- Enrollment target
NCT00014859: Completed study, sponsored by Washington University School of Medicine.
NCT00014859 is a clinical trial that has completed, run by Washington University School of Medicine. The registered enrollment target is 5,176 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00014859 has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- 5,176 participants
- Enrollment target
Study Summary
The purpose of this study is to test the hypothesis that excess, rare, functionally disruptive single nucleotide polymorphisms (SNPs) characterize genes (e.g., the surfactant protein-B gene)(SFTPB) and gene networks (e.g., the pulmonary surfactant metabolic network or other gene networks that regulate alveolar type 2 cell function) associated with increased risk of neonatal respiratory distress syndrome (RDS).
Primary Outcome
Using trio whole exome or whole genome sequencing, next generation sequencing, and in silico prediction of function, discover statistical associations between gene loci with excess, rare, functionally disruptive variants and risk of neonatal respiratory distress syndrome.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,176 participants |
| Start Date | 2001-06-01 |
| Est. Completion | 2024-04-26 |
What the finished NCT00014859 record still lists
NCT00014859 is an observational study that tracks outcomes without assigning an intervention. Its 5,176 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00014859 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00014859 about?
NCT00014859 is a clinical study titled "Epidemiology of Surfactant Protein-B Deficiency". The purpose of this study is to test the hypothesis that excess, rare, functionally disruptive single nucleotide polymorphisms (SNPs) characterize genes (e.g., the surfactant protein-B gene)(SFTPB) and gene networks (e.g., the pulmonary surfactant metabolic network or other gene networks that regula...
What is the current status of trial NCT00014859?
This trial is currently completed. The enrollment target is 5,176 participants. The study started on 2001-06-01. Estimated completion is 2024-04-26.
Who is sponsoring clinical trial NCT00014859?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05135403 · 5,179 participants
ASSURE WCD Clinical Evaluation - Post Approval Study (ACE-PAS)
- NCT05989308 · 5,200 participants · NA
MyChart Proxy Outreach to Parents (MyPOP)
- NCT06008197 · 5,200 participants · Phase 3
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
- NCT06535867 · 5,122 participants
The Efficacy of Conventional Screening Versus mHealth Screening in Early Detection of Oral Potentially Malignant Disorders and Oral Cancer Amongst the Rural Population of Varanasi: A Prospective and Blinded Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI